59
SOUTH SAN FRANCISCO, Calif. — September 2, 2025 — Leads & Copy — Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company, will participate in the H.C. Wainwright 27th Annual Global Investment Conference on September 9, 2025, at 8:30 a.m. ET, featuring a fireside chat.
A live webcast will be available in the Investors section of Nkarta’s website, with a replay archived for approximately 90 days. Nkarta is focused on developing allogeneic, off-the-shelf natural killer (NK) cell therapies for autoimmune diseases, utilizing its cell expansion, cryopreservation platform, proprietary cell engineering technologies, and CRISPR-based genome engineering.
Nadir Mahmood, Nkarta, Inc., nmahmood@nkartatx.com
Source: Nkarta
